Juan J Novoa, Inge M Westra, Esther Steeneveld, Natascha Fonseca Neves, Christiaan H Arendzen, Bahareh Rajaei, Esmée Grundeken, Mehmet Yildiz, Wouter van der Valk, Alison Salvador, Françoise Carlotti, Pascale F Dijkers, Heiko Locher, Cathelijne W van den Berg, Karine I Raymond, Agnete Kirkeby, Christine L Mummery, Ton J Rabelink, Christian Freund, Pauline Meij, Brigitte Wieles
BACKGROUND AIMS: Few human induced pluripotent stem cell (hiPSC) lines are Good Manufacturing Practice (GMP)-compliant, limiting the clinical use of hiPSC-derived products. Here, we addressed this by establishing and validating an in-house platform to produce GMP-compliant hiPSCs that would be appropriate for producing both allogeneic and autologous hiPSC-derived products. METHODS: Our standard research protocol for hiPSCs production was adapted and translated into a GMP-compliant platform...
March 5, 2024: Cytotherapy